Sun Pharmaceutical Update by Epic Research

Sun Pharmaceutical Industries’ one of its subsidiaries has executed a settlement agreement with Novartis Pharmaceuticals Corporation stipulating a dismissal of the lawsuits filed in the United States against the company regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gleevec, Imatinib Mesylate tablets. These tablets are indicated for the treatment of chronic myeloid leukemia.



For Real Time News & Trading Trends Keep Liking Epic Research Private Limited



Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+

Posted in: Indian Market Tips